Corindus Vascular Robotics Inc
Corindus Vascular Robotics — Investor Presentation (September 2018)
15 slides from Corindus Vascular Robotics's investor presentation, Sep 5, 2018
Slide 1: Precision Vascular Robotics
Precision Vascular Robotics Corindus Vascular Robotics (CVRS) September 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward - looking statements” (as such term is defined in Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended), and information relating to the company, that are based on
Slide 3: Corindus: An Overview
3 Corindus: An Overview FDA Clears CorPath GRX 2 nd generation technology for use in PCI Company Goes Public trading on NYSE as CVRS FDA Clears CorPath 200 for use in PCI Mayo Telestenting Partnership established to explore remote treatment FDA Clears 1 st Automated Robotic Move (RoR) first step tow
Slide 4: Corindus' Robotic Technology
• CorPath GRX cleared in late 2016 • Launched in 2017 • ~2,000 robotic CorPath GRX cassettes sold globally PCI Corindus’ Robotic Technology 4 1 CorPath Systems are not indicated for use in neuro interventions. • Ongoing clinical trials • Steering committee established in 2018 • Potential disruptor t
Slide 5: Adding Value in PCI & Peripheral Across Key Stakeholders
Adding Value in PCI & Peripheral Across Key Stakeholders 5 Paradigm Shift in Place Will Drive Adoption 1 Smilowitz N, et al. Robotic - Enhanced PCI Compared to the Traditional Manual Approach. J Invasive Cardiol , 2014;26(7):318 - 321. 2 Campbell PT, et al. The Impact of Precise Robotic Lesion Lengt
Slide 6: Substantial Market Opportunity
~900K Stroke Incidence US 3 NEURO ~33% 4% Treated Substantial Market Opportunity 6 3+ M Procedures WW 1 (~900K US / ~2.2M OUS) PCI Over 2+ M Procedures WW 1 (~875K US / ~1.3M OUS) PERIPHERAL 11% CLI (BTK) Target Market : Expand TAM with remote access Target Market : US (Complex) / OUS (Simple / Comp
Slide 7: Robotics Integrates Into High Tech Care Models
Robotics Integrates Into High Tech Care Models 7 Allow Procedures to be Performed Devices Robotics Imaging Artificial Intelligence Navigation Remote
Slide 8: Procedural Automation
Procedural Automation 8 • High percentage of procedure time is dedicated to wire manipulation • Varying skill levels among operators • Create algorithms based on techniques of highly skilled operators • Reduced procedure time may positively impact patient outcomes Problem Strategy New automated move
Slide 9: Addressing Unmet Needs
Addressing Unmet Needs • Access to treatment in remote/rural locations • Aging patient population • Shortage of skilled specialists • Emergent procedures: T ime to treatment is critical • Increase access to care & reduce time to treatment • Expand capable facility footprint • Enable tele - proctorin
Slide 10: Neurovascular Steering Committee / Milestones
Neurovascular Steering Committee / Milestones 10 Aquilla S. Turk, D.O. Medical University of South Carolina Ricardo A. Hanel , M.D. PhD Baptist Health System Tudor G. Jovin , M.D. University of Pittsburgh Medical Center J. Mocco , M.D. Mt. Sinai Hospital Vitor Mendes Pereria , M.D. Toronto Western H
Slide 11: Stroke: A Serious and Costly Problem
Stroke: A Serious and Costly Problem 11 • Stroke ranks the #5 cause of death in the US (accounts for 1 in 19 deaths) 1 • > 7 million stroke survivors, two - thirds of which live with a moderate - to - severe disability 1 • Each passing minute during stroke results in the loss of ~2 million neurons .
Slide 12: Remote Access Capabilities May Significantly Increase TAM
Remote Access Capabilities May Significantly Increase TAM 12 Ischemic Stroke ~775K Large Vessel Occlusion ~335K Salvageable Tissue ~160K Patients Treated ~35K US Incidence 1 ~900K Stroke • Time to treatment is key in the stroke market • Current treatment paradigm requires treatment within a 24 hour
Slide 13: Financials Snapshot
9 16 23 33 37 41 0 5 10 15 20 25 30 35 40 45 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 Financials Snapshot 13 Revenue $ 0.8 M $ 2.3 M $ 2.4 M $ 4.2 M $ 1.5 M $ 1.7 M 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 ~Cash balance of $34.3M, Debt of $11.6M, 188.9M sh
Slide 14: Clinical Catalysts: Next Months
Clinical Catalysts: Next 12 - 24 Months 14 Key Expected Milestones for Clinical Development Remote • Live remote PCI at TCT 2018 • First - in - human completed by year - end 2018 in India • Planned US clinical trials Neuro • FDA submission for neuro indication by year - end 2018 or early 2019 • Part
Slide 15: Corindus Summary / Key Investment Thesis
Corindus Summary / Key Investment Thesis 15 • Significant progress in technology development and clinical expansion is creating a burning platform for hospitals to build a robotic program • AI / automation and remote access have the potential to add significant value to hospitals, patients, and doct
Corindus Vascular Robotics — Investor Presentation (September 2018) on 6ix